反应详情

Example 169 was prepared according to the procedures described in Example 168 and Example 162 substituting 1-(2-chloro-4-(methylsulfonyl)phenyl)-4-(piperidin-4-yloxy)pyridin-2(1H)-one hydrochloride for 6-methyl-1-(4-(methylsulfonyl)phenyl)-4-(piperidin-4-yloxy)pyridin-2(1H)-one hydrochloride and 2-chloro-5-propylpyrimidine for 2-chloro-5-cyclopropylpyrimidine in Step C. 1H NMR (500 MHz, CDCl3) δ ppm 8.19 (s, 2H), 8.16 (s, 1H), 7.99 (dd, J=8.25, 2.20 Hz, 1H), 7.62 (d, J=8.25 Hz, 1H), 7.06 (d, J=7.70 Hz, 1H), 6.10 (dd, J=7.70, 2.75 Hz, 1H), 6.05 (d, J=2.75 Hz, 1H), 4.55-4.64 (m, 1H), 4.23 (dd, J=11.55, 6.05 Hz, 2H), 3.59-3.69 (m, 2H), 3.14 (s, 3H), 2.43 (t, J=7.42 Hz, 2H), 2.11 (td, J=6.32, 3.30 Hz, 2 H), 1.88 (ddd, J=8.39, 4.40, 4.26 Hz, 2H), 1.55-1.61 (m, 2H), 0.96 (t, 3H). MS (ESI) 503 (M+H).

1. customExample 169 was prepared